Extended Data Fig. 3: Changes in FVC after 12 weeks of treatment with rentosertib stratified by concurrent use of SOC antifibrotic therapy. | Nature Medicine

Extended Data Fig. 3: Changes in FVC after 12 weeks of treatment with rentosertib stratified by concurrent use of SOC antifibrotic therapy.

From: A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial

Extended Data Fig. 3

(a) Absolute change in FVC ± 95% CI in patients not concurrently taking SOC antifibrotic therapy (left) or in patients concurrently taking antifibrotic therapy (right). (b) Absolute change in FVC ± 95% CI by ANCOVA Model with Multiple Imputation assuming missing at random (MAR) in patients not concurrently taking SOC antifibrotic therapy (left) or in patients concurrently taking antifibrotic therapy (right).

Back to article page